

# p53 Dependence of Topoisomerase I Recruitment *in Vivo*<sup>1</sup>

Yinghui Mao, Shoshiro Okada, Long-Sheng Chang, and Mark T. Muller<sup>2</sup>

Department of Molecular Genetics, The Ohio State University [Y. M., S. O., M. T. M.], and Department of Pediatrics, Children's Hospital [L.-S. C.], Columbus, Ohio 43210

## ABSTRACT

DNA damage is attended by rapid recruitment of endogenous type I topoisomerase (topo I) into covalent cleavage complexes with genomic DNA *in vivo*. In contrast, endogenous topoisomerase II  $\alpha$  and  $\beta$  are not stimulated by DNA damage. We show that topo I and p53 are able to associate at arrested topo I-genomic DNA covalent complexes *in vivo*, suggesting that p53 directly stimulates topo I activity and damage to the genome of the afflicted cell. Moreover, cells that express wild-type p53 are most proficient at recruiting topo I after DNA damage; however, the p53 dependence is conditional because topo I recruitment after DNA damage can be restored in p53 mutant cells (containing a single mutant allele) are artificially held in G<sub>1</sub>. In contrast, p53 null mutants do not recruit topo I after DNA damage under any conditions (although camptothecin-dependent topo I/DNA complexes readily form in the nulls). These results show that topo I activation after DNA damage depends on the p53 status of the cell. It also depends upon the cell cycle in a way that is very different from that observed with DNA replication-dependent, camptothecin-mediated DNA breaks. The data suggest a model where p53 activates topo I, which inflicts additional genomic damage after the initial UV damage events. Topoisomerases therefore contribute to the p53 commitment to apoptosis, and topo I might assist in elimination of DNA-damaged cells as part of the cellular proofreading function inherent in the p53 pathway.

## INTRODUCTION

Cellular responses to DNA damage include activation of cell cycle arrest, DNA repair, and in some cases cell death by apoptosis (1–3). The p53 tumor suppressor gene has been proposed as a genomic “guardian” by exerting cell cycle checkpoint control in response to DNA damage (4). After exposure to a wide variety of DNA-damaging agents, p53 expression is “activated” by one or more posttranslational mechanisms that result in a rapid increase in the cellular level of this protein. Functional p53 is required for activation of a G<sub>1</sub> checkpoint, and the resulting growth arrest is thought to allow cells time to repair DNA prior to replication (5–7) or in some cells eradicate DNA damage laden cells that may be precancerous (8). In addition, p53 may influence DNA repair through GADD45, which stimulates the DNA synthesis associated with the excision repair process by forming complexes with proliferating cell nuclear antigen (9). Moreover, p53 may play a more direct role in DNA repair by binding to ERCC3 excision repair factor and several TFIIH-associated factors *in vitro* (10). The positive effects of p53 (*i.e.*, events that enhance the excision repair pathway) compared with negative effects (*i.e.*, events that lead to eradication of DNA damaged cells) may both operate to varying extents, depending upon the degree of DNA damage and tissue environments. Recently, it was reported that wild-type p53 can bind and increase the catalytic activities of topo<sup>3</sup> I *in vitro* and *in vivo* (11, 12). Given that topo I is also a DNA-damaging agent, we

examined p53 effects on topo I-genomic DNA interaction after DNA damage.

Eukaryotic topo I makes single strand breaks in DNA, followed by one or more cycles of controlled rotation, followed by resealing (13). Topo I participates in a variety of DNA templating activities, such as transcription (14–17) and DNA replication (18, 19), presumably to reduce torsional stress in the template. Topo I is also thought to influence genomic instability through illegitimate recombination (20–23). Although topo I is not an essential gene in yeast (24), it is required for embryonic development in *Drosophila melanogaster* (25) and mice (26); therefore, topo I is essential in the context of a multicellular organism.

There have been hints that topo I participates in post-DNA damage response. Distortions in the helix, such as abasic sites and UV photoproducts inhibit the catalytic activity of topo I and/or trap topo I on DNA *in vitro* (27, 28). Previously, our group reported that DNA damage by UV irradiation specifically stimulates the formation of covalent complexes between topo I and DNA *in vivo* (29). We refer to this phenomenon as the topo I/DNA damage response, and in the present work, evidence is presented that this response is strongly dependent upon cell cycle checkpoints activated by p53 after UV-damaged DNA. These findings suggest a model whereby topo I and p53 might cooperate to eliminate damaged genomes from the organism.

## MATERIALS AND METHODS

**Reagents.** The topo I antibody is a human antibody against topo I isolated from serum of scleroderma patients. The topo II $\alpha$  antibody is a rabbit polyclonal antibody directed against the M<sub>r</sub> 170,000 form of human topo II. The topo II $\beta$  antibody is a mouse monoclonal antibody to the M<sub>r</sub> 180,000 form of human topo II. The topo II $\alpha$  antibody was donated by TopoGEN, Inc. (Columbus, OH), and the topo II $\beta$  antibody was a kind gift from Dr. A. Kikuchi. The anti-p53 antibody (Pab 421) was obtained from Oncogene Science (Uniondale, NY). CPT and VP16 were also donated by TopoGEN, Inc. G418 was purchased from Life Technologies, Inc. (Rockville, MD). DMS and cycloheximide were purchased from Sigma Chemical Co. (St. Louis, MO).

**Cell Culture.** The MCF-7 and SK-BR-3 cell lines in this study are derived from human mammary adenocarcinoma. MCF-7 cells express wild-type p53 (30, 31), whereas SK-BR-3 cells carry a deletion in one of the p53 alleles and a point mutation at amino acid 175 in the remaining allele, encoding a nonfunctional p53 protein that is defective in sequence-specific DNA binding (30, 32). Both cell lines are cultured in DMEM supplemented with 10% fetal bovine serum (CellGro, Inc., Herndon, VA). SK-BR-3/hp53 cells are a clonal isolate of SK-BR-3 cells containing the human p53 gene under control by the cytomegalovirus immediate-early promoter. HL60 is a p53-null human leukemia cell line and cultured in RPMI 1640 supplemented with 10% fetal bovine serum (Life Technologies, Inc., Grand Island, NY).

**Transfection.** Freshly plated MCF-7 and SK-BR-3 cells at 50–80% confluence were transfected with 2  $\mu$ g of DNAs per 35-mm dish, using SuperFect transfection reagent (Qiagen, Valencia, CA), according to the manufacturer's instructions. For stable transfection of the wild-type p53 gene into SK-BR-3 cells, cells were split into fresh medium containing 400  $\mu$ g/ml G418 (CellGro, Inc., Herndon, VA) until resistant colonies formed. Colonies were recovered using Scienceware cloning cylinders (Fisher Scientific) and then checked for p53 expression by Western blotting.

**UV Irradiation of Cells.** For UV treatment of cells, culture medium was aspirated, and cell monolayers were washed several times with room temperature PBS (140 mM NaCl, 2.5 mM KCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>, and 1.75 mM

Received 10/26/99; accepted 6/20/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This study was supported by Grant RO1-AG16692 from the NIH, Grant GMC-89165 (to L. S. C.) from the American Cancer Society, and Grant CA16058 from the Ohio State University Comprehensive Cancer Center.

<sup>2</sup> To whom requests for reprints should be addressed, at Department of Molecular Genetics, The Ohio State University, 484 West 12th Avenue, Columbus, OH 43210. Phone: (614) 292-1914; Fax: (614) 292-4702; E-mail: muller.2@osu.edu.

<sup>3</sup> The abbreviations used are: topo, topoisomerase; CPT, camptothecin; VP16, etoposide; DMS, dimethylsulferimidate.

KH<sub>2</sub>PO<sub>4</sub>). The cells were then exposed to a germicidal lamp emitting at 254 nm light at a fluence rate of 2 J/m<sup>2</sup>/s. Immediately after irradiation, medium was replaced, and cells were incubated at 37°C. At indicated times after UV treatment, cells were processed according to the ICT bioassay protocol.

**In Vivo Complex of Topo (ICT) Bioassay.** The method for detecting topo-DNA covalent complexes *in vivo* is described in detail elsewhere (29, 33, 34). After DNA purification on CsCl gradients, DNA concentrations were measured by fluorometry, and fixed concentrations of DNA were blotted onto a slot blot device that was subsequently probed with a topo I antibody. Signals were illuminated using <sup>125</sup>I-labeled protein A (ICN, Costa Mesa, CA) and quantified using phosphorimage analysis.

For analysis of p53-topo I complexes, the ICT bioassay was modified as follows. At 4 h after UV, MCF-7 cells were exposed to 10 mM DMS at room temperature for 1 h to induce protein/protein cross-linking. The ICT bioassay was then carried out, and the presence of p53 in the DNA peak of CsCl gradients was determined by Western slot blotting.

## RESULTS

**UV Irradiation Stimulates Endogenous topo I-DNA Covalent Complex.** The ICT bioassay is an antibody-based method that detects endogenous topo I-DNA covalent complex formation *in vivo* (29, 33, 34). The method has been successfully used to directly evaluate the action of endogenous topo I on genomic DNA in response to DNA repair-related activity in the absence of topo poisons that drive topo I into cleavable complexes. For example, we demonstrated that DNA damage (UV irradiation) stimulates topo I-DNA covalent complex formation in the absence of the topo I poison, CPT. We refer to this as the topo I/DNA damage response (29). The kinetics of response were analyzed in MCF-7 cells after exposure to 10 J/m<sup>2</sup> of UV irradiation. Topo I-DNA covalent complexes were detected rapidly after UV treatment (29). As shown in Fig. 1, within 30 min, the level of topo I-DNA complex increased 1.5–2-fold over that of untreated controls, and the complexes continued to increase through the time when nucleotide excision repair was maximal. Within 5 h, topo I-DNA complexes reached peak level (about 3–4-fold over no incubation) and then gradually receded within one cell cycle. The kinetics of complex formation closely paralleled the p53 profile of response after UV irradiation (5, 6). To confirm that p53 accumulated in the nucleus after UV irradiation, MCF-7 cells were stained with an anti-p53 antibody and examined by indirect immunofluorescence microscopy. UV-treated cells displayed strong nuclear fluorescence; however, untreated controls presented minimal background nuclear staining (data not shown).

**The topo I/DNA Damage Response Does Not Require New Protein Synthesis.** The elevation in endogenous topo I covalent complexes could be a result of new protein synthesis, consequently




Fig. 1. Time course of the topo I/DNA damage response. MCF-7 cells were UV irradiated (10 J/m<sup>2</sup>) and returned to normal growth conditions at 37°C. At the indicated times after irradiation, cells were lysed according to the ICT bioassay. DNA was recovered from the CsCl gradient and pooled, and concentrations were determined by fluorometry. Three concentrations of DNA (6, 2, and 0.6 μg of DNA) were placed on an immuno slot blot. Topo I levels associated with the DNA were measured using an anti-topo I antibody probe as describe in "Materials and Methods." Markers on the left correspond to 6, 2, and 0.6 μg of DNA per slot and times of harvest after UV exposure (hours) are marked along the top.




Fig. 2. Topo I/DNA damage response in the presence of cycloheximide. MCF-7 cells were pretreated with 50 μM cycloheximide (C-hex) for 30 min, then treated with CPT (10 μM for 30 min), UV irradiation (10 J/m<sup>2</sup>, then incubated for 4 h), or untreated (control), followed by the ICT bioassay using topo I antibody as described in "Materials and Methods." Three DNA concentrations (10, 3.3, and 1.0 μg) spotted on the blot are indicated on the left.

giving higher levels of total topo I. Alternatively, preexisting topo I could be activated by p53 or chromatin remodeling factors (35). To examine dependence on new protein synthesis, we determined the effects of cycloheximide on the topo I/DNA damage response. MCF-7 cells were treated (cycloheximide, CPT, and UV) as described in Fig. 2, and the DNA was isolated from the ICT analysis and probed with antibody to topo I. The data show that blocking protein synthesis had no effect on topo I-DNA complexes that were elevated after UV damage. CPT-induced complexes were slightly reduced (<20%) by blocking translation; however, this may be explained by concomitant arrest of S-phase because it is known that CPT-mediated toxicity is greater in S-phase (36, 37).

**topo I/DNA Damage Response Occurs in Cell Lines with Wild-Type and Mutant p53.** Data in Fig. 1 demonstrated that the topo I/DNA damage response parallels the nuclear accumulation of p53, suggesting a role for p53 in the response. To test whether the topo I/DNA damage response is related to p53, we evaluated the response in cell lines with different p53 status. MCF-7 cells express wild-type p53, whereas SK-BR-3 cells carry a deletion in one p53 allele and a point mutation (amino acid 175) in the remaining allele, encoding a nonfunctional p53 protein that is defective in sequence specific DNA binding (30, 32). The HL60 cell line is p53-null. As expected, MCF-7 cells (wild-type p53) showed an elevation in topo I-DNA complex formation after DNA damage (Fig. 3A). In contrast, SK-BR-3 cells and HL60 cells that lack functional p53 did not show UV-induced topo I-DNA complex formation (Fig. 3, B and C). Western blotting data revealed that these results cannot be attributable to differences in topo I protein levels between these cell lines, because all cell lines contain similar amounts of cellular topo I before and after UV treatment (data not shown). Moreover, treating SK-BR-3 cells and HL60 cells with CPT results in similar covalent complex formation relative to the wild-type MCF-7 cells (Fig. 3). Finally, we tested topo I recruitment in transgenic mouse cell lines from animals that were heterozygous for p53 (one allele deleted) compared with homozygous null mutants and obtained consistent results (data not shown). From these collective results, we conclude that deployment of topo I onto the genome after UV exposure is related to the status of p53.

**Restoration of the topo I/DNA Damage Response by p53.** To explore a specific link between p53 and topo I deployment after DNA damage, we corrected the p53 defect in SK-BR-3 cells. An expression plasmid containing wild-type p53 under control of the cytomegalovirus promoter was transfected into SK-BR-3 cells and p53-expressing clones were selected and expanded as stable cell lines (Fig. 4). Three different clones, all expressing p53 (based upon Western blotting) were examined for topo I recruitment after DNA damage. These cell lines gave rise to high levels of topo I-DNA complex formation after UV irradiation (Fig. 4B), compared with the parental SK-BR-3




Fig. 3. Topo I deployment in p53 wild-type and mutant cells after DNA damage. MCF-7 cells (p53 wild-type), SK-BR-3 cells (p53 mutant), and HL60 cells (p53 null) were either treated with CPT (10  $\mu$ M for 30 min), UV irradiation (10 J/m<sup>2</sup>, then incubated for 4 h), or untreated (control), followed by the ICT bioassay using an anti-topo I antibody as probe (see "Materials and Methods"). A, topo I-DNA complexes in MCF-7 cells. B, topo I-DNA complexes in SK-BR-3 cells. C, topo I-DNA complexes in HL60 cells. The DNA concentrations (6, 3, 1.5, and 0.75  $\mu$ g) spotted onto the blot are shown on the left.

cells (Fig. 4A). These data clearly demonstrated a direct link between p53 and the topo I/DNA damage response because the p53 mutant (parental) line and restored clone should be otherwise isogenic. In addition, CPT-induced topo I-DNA covalent complexes were enhanced in the SK-BR-3/hp53 cells. This result suggests that p53 may be directly stimulating topo I activity *in vivo*, or possibly recruiting topo I to sites of DNA damage, which is consistent to previous reports demonstrating that p53 increases the catalytic activity of topo I *in vitro* (11, 12).

**G<sub>1</sub> Arrest Restores the topo I/DNA Damage Response in Some p53 Mutant Cell Lines.** DNA damage is known to stimulate a p53-dependent cell cycle checkpoint response; therefore, p53 mutant cells would not be expected to display growth arrest after UV irradiation. We next examined whether the topo I/DNA damage response in p53 mutants might be restored by artificially imposing a cell cycle blockade after UV exposure. Different p53 mutants were examined. We tested HL-60 cells that are null for p53. The topo I/DNA damage response was clearly missing from these cells, both in G<sub>1</sub> arrested and growing cells (Fig. 5). Controls show that topo I/DNA complexes readily form after CPT treatment as expected; thus, topo I is clearly active in the null cells.

We also examined the topo I response in SK-BR-3 cells, which as noted above carry a deletion in one *p53* allele and a point mutation (amino acid 175) in the other. Consequently, this cell possesses a p53

mutant protein that retains its ability to interact with topo I (11, 38); however, because the mutation destroys DNA binding, the mutant p53 cannot activate genes in the p53 pathway. The topo I/DNA damage response was compared in G<sub>1</sub> arrested and exponentially growing SK-BR-3 cells. The topo I damage response was essentially undetectable in exponentially growing SK-BR-3 cells (Fig. 6A). In contrast, cells that were serum arrested in G<sub>1</sub> clearly demonstrated a strong topo I/DNA damage response (Fig. 6B), and upon release from arrest, the damage response was again lost (Fig. 6C). Cells containing this particular p53 mutation actively recruit topo I after UV damage when arrested in G<sub>1</sub>. Furthermore, these data suggest that the topo I/DNA damage response involves at least two distinct aspects of p53: (a) a cell cycle checkpoint that facilitates topo I recruitment; and (b) a direct stimulation of topo I activity by p53 (see below).

**Topo II Isoforms Respond Differentially to UV Damage.** Topo II complex formation was not stimulated by UV damage (29); however, given that cell cycle checkpoints are activated after UV damage, we modified the experiment to examine the effects of UV damage on topo II isoforms (p170 and p180), which are differentially regulated in the cell cycle (39, 40). The ICT technique will detect topo II-DNA covalent complexes only in the presence of a topo II poison like VP16, and both endogenous forms of p170 and p180 are trapped on the genome (Table 1). In p53 wild-type cells, UV treatment reproducibly reduced p170 complexes, whereas p180 complexes were unaffected. Thus, although topo II is not directly stimulated by DNA damage (like




Fig. 4. Restoration of the topo I/DNA damage response in SK-BR-3/hp53 cells. SK-BR-3 cells were stably transfected with wild-type *p53* gene and assayed for the topo I/DNA damage response as described in "Materials and Methods." These p53 revertant cells (SK-BR-3/hp53-2, -5, and -12; B) or the parental p53 mutant cell line (A) were treated with CPT (10  $\mu$ M for 30 min), UV irradiation (10 J/m<sup>2</sup>, then incubated for 4 h), or untreated (control), followed by the ICT bioassay with the anti-topo I antibody probe. Three DNA concentrations (6, 2, and 0.6  $\mu$ g) were tested.




Fig. 5. topo I/DNA damage response in G<sub>1</sub> arrested p53 null cells. HL60 cells were arrested in G<sub>1</sub> phase using double thymidine block. Both exponentially growing cells (A) and G<sub>1</sub> arrested cells (B) were treated with CPT (10 μM for 30 min), UV irradiation (10 J/m<sup>2</sup>, then incubated for 4 h), or untreated (control). ICT bioassays were performed using an anti-topo I antibody as described in "Materials and Methods." Three DNA concentrations (6, 2, and 0.6 μg) spotted on the blot are indicated on the left.




Fig. 6. Topo I/DNA damage response in G<sub>1</sub>-arrested p53 mutant cells. SK-BR-3 cells were arrested in G<sub>1</sub> phase using serum starvation. Both exponentially growing cells (A) and G<sub>1</sub>-arrested cells (B) were treated with CPT (10 μM for 30 min), UV irradiation (10 J/m<sup>2</sup>, then incubated for 4 h), or untreated (control). In C, cells either arrested in G<sub>1</sub> phase or released were treated with UV irradiation 10 J/m<sup>2</sup> and then incubated for 4 h. After release, cells that traversed the replicative cycle were determined by pulse label with [<sup>3</sup>H]thymidine. ICT bioassays were performed using an anti-topo I antibody as described in "Materials and Methods." Three DNA concentrations (6, 2, and 0.6 μg) spotted on the blot are indicated on the left.

topo I), VP16-mediated activity was clearly altered in the case of p170.

**p53 and Topo I-DNA Covalent Complexes Associate *in Vivo*.** It has been reported that the p53 protein and topo I physically interact (11, 12). To determine whether p53 is physically associated with topo

I when the latter is arrested in a cleavable complex *in vivo*, we modified the ICT bioassay to examine protein/protein binding *in vivo*. When topo I-DNA complexes were maximal (4 h after UV treatment), MCF-7 cells were exposed to DMS, a bifunctional protein/protein cross-linking reagent, to test for the presence of p53 in the DNA peak of the CsCl gradient (Fig. 7). If p53 binds topo I, which itself is covalently trapped on the genome, then we should detect p53 associated with DNA in the ICT-CsCl gradient (Fig. 7A). The presence of topo I and p53 was examined by Western blotting of the DNA peak fractions (pooled). The p53 signal, detected in the absence of DMS, reflects the background signal for p53 (because the signal was not increased with increasing DNA concentration). In contrast, exposure to DMS resulted in a significant increase in p53 signal when 2 μg of

Table 1 VP16-induced topo II isoform complex formation before and after UV treatment<sup>a</sup>

UV	VP16 (50 μg/ml)	p170 signal <sup>b</sup>	p180 signal <sup>b</sup>
-	-	0	0
-	+	24 ± 2	38 ± 1.5
20 J/m <sup>2</sup>	+	8 ± 2.4	44 ± 3.6
100 J/m <sup>2</sup>	+	ND <sup>c</sup>	40 ± 1.7

<sup>a</sup> MCF-7 cells were treated with UV irradiation or untreated. After 2 h, cells were treated with 50 μM etoposide (VP16) for 30 min and then followed by the ICT bioassay with topo IIα and topo IIβ antibodies (see "Materials and Methods").

<sup>b</sup> Signals are expressed as ng topo II/μg genomic DNA from CsCl gradient peak.

<sup>c</sup> ND, not detectable.




Fig. 7. Topo I-DNA-p53 covalent complex formation *in vivo*. MCF-7 cells were treated with UV (10 J/m<sup>2</sup>) and then incubated for 3 h at 37°C. The cells were scraped up and placed in 1.7-ml microcentrifuge tubes, washed with PBS twice, and resuspended in HEPES buffer (pH 8.5-9.0). DMS was added to 10 mM, and the cells were incubated for 1 h at room temperature. The cells were lysed with detergent, and DNA was purified from CsCl according to the ICT bioassay. Two DNA concentrations (6 and 2 μg) were spotted onto the blot, which was probed with either anti-topo I or anti-p53 antibodies. A diagram of the expected results is illustrated in A. In the absence of DMS, only topo I will be covalently trapped on genomic DNA; in the presence of the cross-linker, p53 should be detected in the DNA peak if p53/topo I make physical contact that can be cross-linked with DMS. B shows the Western slot blot results using either p53 antibody or topo I antibody. Low DNA concentration is on the right and high DNA concentration is on the left of each blot, as indicated on the top. C shows the Western slot blot results with the topo I antibody after immunoprecipitating the pooled DNA fractions with the p53 antibody.

genomic DNA were used, and a commensurate increase in p53 signal was observed using 6  $\mu\text{g}$  of DNA (Fig. 7B). Note, however, that these data do not unambiguously prove that p53 is physically dragged into the DNA peak by topo I because p53 could be trapped by linkage to another (as yet unknown) DNA binding protein. Although this possibility seems remote given the known association between p53 and topo I *in vitro* (11, 12), an additional control was carried out to examine this possibility. DNA peak fractions off the CsCl gradient were pooled and digested extensively with DNase I to release bound proteins. We then performed an immunoprecipitation with an anti-p53 antibody, recovered the precipitate, and probed with topo I antibody. The data show clearly a complex formation between topo I and p53 (Fig. 7C). To the best of our knowledge, this is the first demonstration that endogenous p53 and topo I are together at the site of the topo-DNA covalent (cleavable) complex *in vivo*.

In the absence of the DMS cross-linker, we detected topo I recruitment on the genome as shown above (Fig. 7B); however, treatment with the protein/protein cross-linker stimulated topo I signal in the DNA peak anywhere from 2- to 5-fold (in different experiments), suggesting that topo I may (in addition to p53) be interacting with itself or in some kind of self protein/protein clustering mode as a complex.

## DISCUSSION

Previously, we reported that UV-induced DNA damage stimulates topo I-DNA covalent complex formation *in vivo* (29). A direct role for topo I in the nucleotide excision repair process was proposed because repair-deficient XPD cells are additionally compromised in their ability to recruit topo onto the genome after UV irradiation. We have now extended our initial observations, and relevant findings can be summarized as follows:

(a) The kinetics of topo I covalent complex formation after UV irradiation of intact cells closely parallels the nuclear accumulation of p53. In response to DNA damage, cells normally undergo a p53-dependent cell cycle arrest, DNA repair, or apoptosis. Stimulation of topo I activity by p53 (11, 12) suggests a functional relationship between these two proteins involving in DNA damage response.

(b) MCF-7 cells, expressing wild-type p53, are proficient in the topo I/DNA damage response. In contrast, the SK-BR-3 cells expressing mutant p53 show very little topo I response. These data suggest that p53 may stimulate topo I-DNA interactions, leading to arrested covalent complexes on the genome. It is important to note that cells expressing mutant p53 sustain just as much DNA damage (UV adducts) as do wild-type p53 expressing cells per given UV dose; however, p53 wild-type cells are much more proficient with regard to topo I deployment, as measured by ICT after damage. Lanza *et al.* (41) and work from this laboratory (29) have confirmed that topo I cleavage/religation equilibrium is sensitive to helical distortions associated with UV lesion formation. Because UV-damaged DNA can stabilize topo I cleavable complexes and because p53 activates topo I activity on DNA, topo I might assist in promoting the cell down a path of apoptosis by inflicting genome damage (see points that follow).

(c) Topo I/DNA damage can be effectively restored in SK-BR-3 (mutant) cells when providing a wild-type p53 gene. Because a single gene replacement is sufficient to restore topo I-DNA complex formation after DNA damage, we conclude that p53 is a key component in the response. All of the p53 wild-type revertants we tested were proficient in the topo I/DNA damage response, thereby arguing against clonal variation independent of p53.

(d) The topo I/DNA damage response is conditionally dependent upon the p53 status. In one particular p53 mutation (point mutation in the DNA binding domain), cells that are exponentially growing do not

recruit topo I after DNA damage; however, by blocking cell cycle traverse in  $G_1$ , topo I-DNA complex formation after UV treatment could be restored. This is consistent with the previous report indicating that post-UV survival of p53 mutant cells is enhanced by imposing a cell cycle checkpoint (7). In addition, it has been reported that this particular p53 mutant can still physically interact with topo I. Interpretation of these collective results is difficult because of the complexity of the pathways, and additional data will be required to clarify the situation. Basically, there are two models. One model suggests that p53 may promote cell cycle arrest to facilitate DNA repair, as proposed by Linke *et al.* (7). Topo I being a repair factor and also responsive to helical distortion or abasic sites (28) could explain why cleavable complexes are elevated during the periods of excision repair. Another model suggests that p53-driven checkpoints stably withdraw DNA-damaged cells from the cycle to ensure that DNA replication does not proceed into or through damaged template. In this case, topo I, perhaps under the stimulatory influence of p53 (11, 12), might contribute to the DNA damage by forming covalent complexes that we detect in our ICT bioassay. In this way, topo I and p53 cooperate to inflict irreparable damage and permanent withdrawal of the cell from the replicative pool of cells.

(e) In support of the second model described above, our *in vivo* cross-linking data show a physical association between p53 and topo I. Although others have reported p53/topo I binding (11, 12), this is the first demonstration that p53 and topo I form molecular complexes at the actual site of DNA cleavage/religation in chromatin. Our cross-linking experiments will only detect p53 bound to topo I that has been covalently coupled (trapped) on the genome through its catalytic cycle of action on DNA. This type of experiment reveals that topo I and p53 are either in a complex or close physical contact immediately prior to (or during) the arrest of the covalent "cleavable" complex. We speculate that topo I and p53 are part of a multiprotein complex and that p53 directly stimulates topo I cleavages (12). Our DMS cross-linking data also suggest that topo I itself is in a self-cluster modality because the amount of topo I detected in the DNA peak can be increased by protein-protein cross-linking. Because topo I is a monomeric protein, it is surprising that it can be detected in a cluster of activity unless its function is to pepper the genome with single strand breaks. It is also possible that topo I interacts with other p53 interactive proteins in chromatin. For example, it has been proposed that p53 plays a direct role in DNA repair by stimulating other DNA binding proteins; p53 binds GADD45, which forms complexes with proliferating cell nuclear antigen, to directly stimulate the DNA synthesis associated with the nucleotide excision repair process (9, 31). The reduction of nucleotide excision repair ability in *gadd45<sup>-/-</sup>* mouse embryo fibroblasts fits nicely with the idea of a role for Gadd45 in cellular DNA repair (35). Recently, it was also shown that GADD45 can facilitate topo I in the presence of core histones *in vitro* (35). These data suggest that p53/GADD45 might enhance the ability of topo I to recognize or be recruited to altered chromatin structures formed as a result of DNA damage.

(f) The topo I/DNA damage response does not require new protein synthesis (Fig. 2), indicating that preexisting topo I is affected. Elevated topo I-DNA complexes may be explained by the formation of a higher affinity DNA substrate (*i.e.*, helical distortions; Refs. 29 and 41), alterations that promote topo I access to underlying DNA in chromatin (*e.g.*, chromatin remodeling; Refs. 35) or direct stimulation of topo I by p53 (11, 12). It is not unreasonable to propose that all these events cooperate to give the topo I/DNA damage response.

(g) Topo II isoforms are clearly not stimulated to form covalent complexes after DNA damage such as topo I (29). To examine topo II with the ICT bioassay, it was necessary to treat the cells with a topo II poison to trap complexes. UV irradiation clearly had a strong

impact on p170 because covalent complexes were reduced on average 4-fold. There was no detectable effect on p180. The most likely explanation is that DNA damage imposed a cell cycle checkpoint that affected the p170 isoform, which is strongly cell cycle regulated, whereas p180, which is not a periodic enzyme, was not altered.

In summary, there are two models that explain p53 and cell cycle-dependent topo I activity after DNA damage. The first model is that topo I may be an active participant in excision repair. We showed previously that the topo I/DNA damage response is aborted in the repair-deficient XPD cells (29). Nucleotide excision repair is a complex process that involves damage recognition, incision of the damaged strand, excision of the lesion containing oligonucleotides, synthesis of new DNA, and ligation. Topo I could be involved at any one (or all) of these steps; however, it is also likely that some chromatin activation or restaging is necessary prior to topo I activity at repair patches, because topo I cannot compete with bulk chromatin for DNA access. In this regard, Gadd45, a p53-responsive factor, might drive local chromatin modifications to facilitate topo I accessibility (35). A second model is that topo I contributes to the general demise of the cell by contributing to genomic damage and subsequent p53-dependent elimination through apoptosis. In this model, topo I assists in forcing cell cycle checkpoints by inflicting DNA cleavage complexes and elimination of cells destined to be precancerous. The clustering of topo I on the genome after DNA damage and the p53 stimulation of topo I cleavage activity support this model. These two models are not mutually exclusive, and it is possible that DNA damaged cells exist in a balance between repair (or resurrection) and apoptosis. The outcome of the process is stochastic and depends on a number of unknown factors in the p53 pathway in addition to the cell cycle phase and degree of damage. Additional experiments are ongoing to elucidate the models.

## ACKNOWLEDGMENTS

We thank Michael C. Ostrowski and Lee F. Johnson for critical input and helpful discussions. In addition, we gratefully acknowledge a gift of p53 heterozygous and homozygous null mutant mouse cell lines from Dr. Gustavo Leone.

## REFERENCES

- Canman, C. E., Gilmer, T. M., Coutts, S. B., and Kastan, M. B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. *Genes Dev.*, 9: 600–611, 1995.
- Smith, M. L., and Fornace, A. J., Jr. The two faces of tumor suppressor p53. *Am. J. Pathol.*, 148: 1019–1022, 1996.
- Kaufmann, W. K., and Pauls, R. S. DNA damage and cell cycle checkpoint. *FASEB J.*, 10: 238–247, 1996.
- Cox, L. C., and Lane, D. P. Tumor suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. *BioEssays*, 17: 501–508, 1995.
- Lane, D. The regulation of p53 function: Steiner Award Lecture. *Int. J. Cancer*, 57: 623–627, 1994.
- Levine, A. J., Perry, M. E., Chang, A., Silver, A., Dittmer, D., Wu, M., and Welsh, D. The Walter Habert Lecture: the role of the p53 tumor-suppressor gene in tumorigenesis. *Br. J. Cancer*, 69: 409–416, 1994, 1993.
- Linke, S. P., Klarkin, K. C., and Wahl, G. M. p53 mediates permanent arrest over multiple cell cycles in response to  $\gamma$ -irradiation. *Cancer Res.*, 57: 1171–1179, 1997.
- Hill, L. L., Ouhtit, A., Loughlin, S. M., Kripke, M. L., Ananthaswamy, H. N., and Owen-Schaub, L. B. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. *Science (Washington DC)*, 285: 898–900, 1999.
- Smith, M. L., Chen, I-T., Zhan, Q., Bae, I., Chen, C-Y., Gilmer, T. M., Kastan, M. S., O'Connor, P. M., and Fornace, A. J. Interaction of the p53-regulate protein GADD45 with proliferating cell nuclear antigen. *Science (Washington DC)*, 266: 1376–1380, 1994.
- Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J. M., Wang, Z., Friedberg, E. C., Evans, M. K., Taffe, B. G., Bohr, V. A., Weeda, G., Hoiemakers, J. H. J., Forrester, K., and Harris, C. C. p53 modulation of TFIIH-associated nucleotide excision repair activity. *Nat. Genet.*, 10: 188–195, 1995.
- Albor, A., Kaku, S., and Kulesz-Martin, M. Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants. *Cancer Res.*, 58: 2091–2094, 1998.
- Gobert, C., Bracco, L., Rossi, F., Olivier, M., Tazi, J., Lavelle, F., Larsen, A. K., and Riou, J. F. Modulation of DNA topoisomerase I activity by p53. *Biochemistry*, 35: 5778–5786, 1996.
- Stewart, L., Redinbo, M. R., Qiu, X., Hol, W. G. J., and Champoux, J. J. A model for the mechanism of human topoisomerase I. *Science (Washington DC)*, 279: 1534–1541, 1998.
- Muller, M. T., Pfund, W. P., Mehta, V. B., and Trask, D. K. Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. *EMBO J.*, 4: 1237–1243, 1985.
- Merino, A., Madden, K. R., Lane, W. S., Champoux, J. J., and Reinberg, D. DNA topoisomerase I is involved in both repression and activation of transcription. *Nature (Lond.)*, 365: 227–232, 1993.
- Wu, H-Y., and Liu, L. F. DNA looping alters local DNA conformation during transcription. *J. Mol. Biol.*, 219: 615–622, 1991.
- Kertzschmar, M., Meisterernst, M., and Roeder, R. G. Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. *Proc. Natl. Acad. Sci. USA*, 90: 11508–11512, 1993.
- Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. *Cancer Res.*, 49: 6365–6368, 1989.
- D'Arpa, P., Beardmore, C., and Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. *Cancer Res.*, 50: 6919–6924, 1990.
- Wang, J. C., Caron, P. R., and Kim, R. A. The role of DNA topoisomerases in recombination and genome stability: a double-edged sword. *Cell*, 62: 403–406, 1990.
- Wang, J. C. DNA topoisomerase: why so many. *J. Biol. Chem.*, 266: 6659–6662, 1991.
- Zhu, J., and Schiestl, R. H. Topoisomerase I involvement in illegitimate recombination in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.*, 16: 1805–1812, 1996.
- Wang, J. C. DNA topoisomerases. *Annu. Rev. Biochem.*, 65: 635–692, 1996.
- Yanagida, M., and Sternglanz, R. Genetics of DNA topoisomerases. In: N. R. Cozzarelli and J. C. Wang (eds.), *DNA Topology and Its Biological Effects*, pp. 299–320. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1990.
- Lee, M. P., Brown, S. D., Chen, A., and Hsieh, T-S. DNA topoisomerase I is essential in *Drosophila melanogaster*. *Proc. Natl. Acad. Sci. USA*, 90: 6656–6660, 1993.
- Morham, S. G., Kluckman, K. D., Voulomanos, N., and Smithies, O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. *Mol. Cell. Biol.*, 16: 6804–6809, 1996.
- Pedriani, A. M., and Ciarrocchi, G. Inhibition of *Micrococcus luteus* DNA topoisomerase I by UV photoproducts. *Proc. Natl. Acad. Sci. USA*, 80: 1787–1791, 1983.
- Pourquier, P., Ueng, L-M., Kohlhagen, G., Mazumder, A., Gupta, M., Kohn, K. W., and Pommier, Y. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. *J. Biol. Chem.*, 272: 7792–7796, 1997.
- Subramanian, D., Rosenstein, B. S., and Muller, M. T. Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation *in vivo*: possible relationship with DNA repair. *Cancer Res.*, 58: 976–984, 1998.
- Blagosklonny, M. V., Toretzky, J., and Weckers, L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. *Oncogene*, 11: 933–939, 1995.
- Kastan, M. B., Zhao, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Welsh, W. V., Plunkett, B., Vogelstein, B., and Fornace, A. J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. *Cell*, 71: 587–597, 1992.
- Kovach, J. S., McGovern, R. M., Cassady, I. D., Swason, S. K., Wald, L. E., Vogelstein, B., and Sommer, S. S. Direct sequencing from touch preparations carcinomas: analysis of p53 mutation in breast carcinomas. *J. Natl. Cancer Inst.*, 83: 1004–1009, 1991.
- Subramanian, D., Kraut, E., Staubus, A., Young, D. C., and Muller, M. T. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. *Cancer Res.*, 55: 2097–2103, 1995.
- Subramanian, D., Furbee, C. S., and Muller, M. T. ICE bioassay: isolating *in vivo* complexes of Enzyme to DNA. In: M. Bjornsti and N. Osheroff (eds.), *Protocols for DNA Topoisomerases*, 1999.
- Carrier, F., Georgel, P. T., Pourquier, P., Blake, M., Kontny, H. U., Antinore, M. J., Gariboldi, M., Myers, T. G., Weinstein, J. N., Pommier, Y., and Fornace, A. J., Jr. Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. *Mol. Cell. Biol.*, 19: 1673–1685, 1999.
- Li, L. H., Fraser, T. J., Olin, E. J., and Bhuyan, B. K. Action of camptothecin on mammalian cells in culture. *Cancer Res.*, 32: 2643–2650, 1972.
- Liu, L. F. DNA topoisomerase poisons as antitumor drugs. *Annu. Rev. Biochem.*, 58: 351–375, 1989.
- Gobert, C., Skladanowski, A., and Larsen, A. K. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant cells. *Proc. Natl. Acad. Sci. USA*, 96: 10355–10369, 1999.
- Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. *Cell Growth Differ.*, 2: 209–214, 1991.
- Capranico, G., Tinelli, S., Austin, C. A., Fisher, M. L., and Zunino, F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. *Biochim. Biophys. Acta Gene Struct. Express.*, 1132: 43–48, 1992.
- Lanza, A., Tornaletti, S., Rodolfo, C., Scanavini, M. C., and Pedriani, A. M. Human DNA topoisomerase I-mediated cleavages stimulated by ultraviolet light-induced DNA damage. *J. Biol. Chem.*, 271: 6978–6986, 1996.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## p53 Dependence of Topoisomerase I Recruitment *in Vivo*

Yinghui Mao, Shoshiro Okada, Long-Sheng Chang, et al.

*Cancer Res* 2000;60:4538-4543.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/60/16/4538>

**Cited articles** This article cites 38 articles, 22 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/60/16/4538.full#ref-list-1>

**Citing articles** This article has been cited by 14 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/60/16/4538.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/60/16/4538>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.